BDTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BDTX is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock has some supportive catalysts like a strong cash position and improved analyst targets, but the current technical trend is still weak, earnings remain loss-making, and the options setup is only mildly bullish rather than a clear confirmation. For an impatient investor who does not want to wait for a better entry, this is not an attractive immediate buy.
The trend is bearish to neutral. MACD histogram is below zero and still expanding negatively, which signals weakening momentum. RSI_6 at 44.7 is neutral and does not show oversold strength. Moving averages are bearish with SMA_200 > SMA_20 > SMA_5, indicating the stock is still trading below a healthy uptrend structure. Price at 2.80 is only slightly above the pivot of 2.764, with resistance at 3.024 and support at 2.504, so the stock is sitting in a range without a strong breakout signal. The short-term pattern estimate is mixed, with limited next-day upside and a weak next-week outlook.
["Q1 GAAP EPS of -0.16 beat expectations by $0.02.", "Cash and investments of $118.3 million should fund operations into the second half of 2028.", "Wedbush raised its price target to $14 from $13 and kept an Outperform rating.", "H.C. Wainwright raised its price target to $11 from $10 and kept a Buy rating.", "Options flow shows a bullish tilt with a 0.46 open interest put-call ratio."]
["The market reacted tepidly to earnings, showing cautious sentiment.", "Revenue in the latest quarter was still 0, so there is no commercial sales growth.", "Net income and EPS remain negative, reflecting ongoing profitability issues.", "MACD is negative and worsening, confirming weak price momentum.", "Bearish moving averages indicate the stock is still in a downtrend.", "No strong AI Stock Picker or SwingMax signal is present today."]
In the latest quarter, 2025/Q4, Black Diamond Therapeutics reported revenue of 0, which is flat year over year and shows no commercial revenue growth. Net income fell to -15.116 million, down 5.44% YoY, and EPS declined to -0.26, down 7.14% YoY. Gross margin was 100, but that is not very meaningful without revenue. The most recent reported quarter highlighted continued losses, although the company’s Q1 GAAP EPS of -0.16 beat estimates by $0.02 and cash runway appears long, extending into the second half of 2028.
Analyst sentiment has improved recently. On 2026-04-29, H.C. Wainwright raised its target to $11 from $10 and kept a Buy rating. On 2026-03-17, Wedbush raised its target to $14 from $13 and kept an Outperform rating after quarterly results and clinical development updates. The Wall Street view is constructive on the pipeline and cash runway, but the cautious market reaction and lack of revenue show that the bullish case is still mostly based on future clinical success rather than current fundamentals.
